5 terminated, 4 recruiting, 2 completed, 1 not yet recruiting. 4 Phase 2, 3 Not applicable, 2 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Terminated 3, Recruiting 1 |
| Not applicable | 3 | Completed 1, Recruiting 1, Terminated 1 |
| Phase 1 | 2 | Terminated 2 |
| Phase 3 | 2 | Not yet recruiting 1, Recruiting 1 |
Follow Metastatic Renal Cancer: new trials by email Literature Review of Metastatic Renal Cancer trials Research Report on Metastatic Renal Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Lu-177 PSMA Treatment in Cell Renal Carcinoma Lu-177 PSMA-617 - Metastatic Renal Cancer | Phase 3 | Not yet recruiting | Ankara University | 20 | 2026-05-01 | 2026-02-27 |
| A Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma Sasanlimab, Palbociclib, Axitinib - Metastatic Renal Cell Carcinoma, Metastatic Renal Cancer | Phase 2 | Recruiting | Stephanie Berg | 25 | 2025-11-24 | 2026-08-20 |
| CAIX PET/ CT Guided Radiation Therapy in CcRCC. PETCT-guided radiation therapy - Radiation Therapy, Metastatic Renal Cancer | Not applicable | Recruiting | Peking University First Hospital | 70 | 2025-11-01 | 2026-04-20 |
| SABR Combined With Targeted Therapy and Anti-PD-1 for Recurrent or Metastatic Renal Cancer Radiation therapy, Targeted and immunotherapy - Radiation Therapy, Metastatic Renal Cancer | Recruiting | Peking University First Hospital | 300 | 2024-02-02 | 2026-01-28 | |
| Measuring Oncological Value of Exercise and Statin Guided physical exercise, Atorvastatin, Independent exercise - Prostate Cancer, Breast Cancer | Phase 3 | Recruiting | Tampere University Hospital | 240 | 2023-03-31 | 2025-06-27 |
| Ketogenic Diet for Patients Receiving Treatment for Metastatic Renal Cell Carcinoma Ketogenic diet - Metastatic Renal Cancer | Not applicable | Completed | University Hospital, Angers | 20 | 2020-07-22 | 2024-08-16 |
| Safety and Compliance of Renal Cancer Patients Treated by Non-IV Drugs observance of oral drug treatment - Metastatic Renal Cancer, Stage III Renal Cell Cancer | Unknown | Institut Cancerologie de l'Ouest | 158 | 2016-03-25 | 2018-10-15 | |
| Everolimus Modulation of Anti-tumor T CD4 Immune Responses Biological samples - Metastatic Renal Cancer | Not applicable | Terminated | Centre Hospitalier Universitaire de Besancon | 14 | 2015-11-01 | 2022-05-16 |
| PRednisone Plus EVerolimus in Patients With Metastatic Renal Cell Cancer After Failure of VEGFR -TKI Prednisone + Everolimus - Metastatic Renal Cancer | Phase 2 | Terminated | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | 8 | 2015-09-22 | 2018-01-16 |
| Perfusion CT as a Predictor for Response to Antiangiogenic Therapy in Patients With Metastasized Renal Cell Carcinoma Perfusion-CT - Metastatic Renal Cancer | Completed | Ludwig-Maximilians - University of Munich | 60 | 2012-04-01 | 2018-10-02 | |
| Modified White Blood Cells That Secrete IL-2 and Express a Protein That Targets the ESO-1tumor Protein for Metastatic Cancer Fludarabine, Cyclophosphamide, IL-12 & Anti-NY ESO1 TCR PBL - Metastatic Cancer, Metastatic Melanoma | Phase 1 | Terminated | National Cancer Institute (NCI) | 2 | 2011-10-06 | 2019-01-08 |
| MAGE-A3/12 Metastatic Cancer Treatment With Anti-MAGE-A3/12 TCR-Gene Engineered Lymphocytes PG13-MAGE-A3 TCR9W11 (anti-MAGE-A3/12 TCR) Transduced Autologous Peripheral Blood Lymphocytes, Aldesleukin, Cyclophosphamide - Metastatic Cancer, Metastatic Renal Cancer | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 9 | 2010-12-01 | 2015-10-28 |
| Phase II Study of Aldesleukin (IL-2) Following the Administration of Zanolimumab (Anti-CD4mAb) in Metastatic Melanoma and Metastatic Renal Cancer Zanolimumab, Aldesleukin - Metastatic Melanoma, Metastatic Renal Cancer | Phase 2 | Terminated | National Cancer Institute (NCI) | 9 | 2010-06-01 | 2015-10-28 |
Kidney Neoplasms (13) · Carcinoma, Renal Cell (7) · Melanoma (3) · Neoplasm Metastasis (2) · Breast Neoplasms (1) · Ovarian Neoplasms (1) · Prostatic Neoplasms (1)
Female Urogenital Diseases (13) · Female Urogenital Diseases and Pregnancy Complications (13) · Kidney Diseases (13) · Male Urogenital Diseases (13) · Neoplasms (13) · Neoplasms by Site (13) · Urogenital Diseases (13) · Urogenital Neoplasms (13) · Urologic Diseases (13) · Urologic Neoplasms (13) · Neoplasms by Histologic Type (9) · Adenocarcinoma (7) · Carcinoma (7) · Neoplasms, Glandular and Epithelial (7) · Skin Diseases (4)
Cyclophosphamide (2) · Interleukin-2 (2) · aldesleukin (2) · fludarabine (2) · Adenosine Monophosphate (1) · Atorvastatin (1) · Axitinib (1) · Cytidine Triphosphate (1) · Diet, Ketogenic (1) · Everolimus (1) · Immunotherapy (1) · Interleukin-12 (1) · Pluvicto (1) · Prednisone (1) · Radiotherapy (1)
National Cancer Institute (NCI) (3) · Peking University First Hospital (2) · Ankara University (1) · Centre Hospitalier Universitaire de Besancon (1) · Institut Cancerologie de l'Ouest (1) · Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS (1) · Ludwig-Maximilians - University of Munich (1) · Stephanie Berg (1) · Tampere University Hospital (1) · University Hospital, Angers (1)
United States (4) · France (3) · China (2) · Finland (1) · Germany (1) · Italy (1)
Steven A Rosenberg, M.D. (2) · Alexander Sterzik, Dr. med. (1) · Anno Graser, Prof. Dr. med. (1) · David S Schrump, M.D. (1) · Jozefina Casuscelli, Dr. med. (1) · Michael Staehler, Prof. Dr. med. (1) · Stephanie Berg, DO (1) · Teemu Murtola, MD PhD Prof (1) · Ugo De Giorgi, MD (1)
PMID 23377668, PMID 23861247, PMID 28546463
2019 (1)